Navigation Links
Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
Date:8/21/2008

com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before FDA can be applied for and the FDA may not approve the pandemic vaccine even if further trial results are similar to those disclosed herein; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
2. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
3. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
4. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
7. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
8. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
9. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
10. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... IRVINE, Calif. , Dec. 19, 2014 /PRNewswire/ ... today that Siddhartha Kadia, Ph.D. has joined the ... and Chief Executive Officer and a director of ... high-precision laboratory testing, evaluation and analytical services to ... Prior to joining Evans Analytical Group, ...
(Date:12/19/2014)... , Dec. 19, 2014 In today,s ... product,s web presence to reflect the needs of ... particular, must meet the needs of key stakeholders ... According to recent research by ... of the participating companies averaged more than $100,000 ...
(Date:12/19/2014)... Somewhere between dropping five pounds and cooking ... Audicus , a next-generation hearing aids company, will ... Hearing loss is the third most common ... is often unaddressed. Forty-eight million Americans have hearing loss, ... mainly due to price. Hearing aids traditionally cost $7,000 ...
Breaking Medicine Technology:Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Building a Best-in-Class Pharma Global Brand Website 2Audicus Will Help People Resolve to Hear Better in 2015 2
(Date:12/20/2014)... California (PRWEB) December 20, 2014 Developers ... the release of a new plugin for Final Cut ... Studios. , “TranSlice Volume 5 allows users to create ... draw it.” Said Christina Austin, CEO of Pixel Film ... level of professionalism while maintaining an easy to use ...
(Date:12/19/2014)... Today, Balfleet.com , a leading dress company of ... promotion. All the old and new customers can get ... is well-known for its high quality trendy women’s dresses, ... and more. Its formal dresses are quality made and ... create an elegant look when paired with any accessory. ...
(Date:12/19/2014)... 19, 2014 The Plantrician ... developing educational events, tools and resources for healthcare ... School , the world’s leading online cooking school, ... human being needs: Culinary Rx. As an online ... Culinary Rx, scheduled for debut spring 2015, will ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 An evening dress ... in a lady’s closet. Discount-Dress.com, a distinguished dresses retailer, has ... buy beautiful dresses in this great shopping platform. Customers ... to the staff's hard work, Discount-Dress.com has been accepted and ... a faster and easier shopping stage for clients. In order ...
(Date:12/19/2014)... All children should have their eyesight checked between the ... experts say. The new vision-screening guidelines for preschool-aged ... National Center for Children,s Vision Health. The panel ... for eye problems, particularly vision issues that require ... strabismus (a disorder of eye alignment). Early detection ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Preschoolers Need Eye Screening, Experts Say 2
... ED drug delayed disease progression, researchers found , , WEDNESDAY, ... used to treat erectile dysfunction, appears effective in treating ... by high blood pressure in the arteries that supply ... condition can become tired, dizzy and short of breath, ...
... 28 Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced ... upcoming Oppenheimer 19th Annual,Healthcare Conference on Tuesday, November 4th ... and at the Barclays Capital Small & Mid-Cap,Healthcare Forum ... Seventh Avenue in New York., The live and ...
... INDIANAPOLIS, Oct. 28 WellPoint, Inc. (NYSE:,WLP) announced ... at the,following conferences:, -- Oppenheimer 19th Annual ... Eastern Standard Time ("EST"); and, -- 2008 ... at,9:30 a.m. Mountain Standard Time (11:30 a.m. EST)., ...
... Mass., Oct. 28 Biopure Corporation,(Nasdaq: BPUR ... notice from the,Medicines Control Council (MCC) of South ... Hemopure [hemoglobin glutamer-250,(bovine)], Biopure,s oxygen therapeutic for human ... to appeal the decision promptly and,expects to continue ...
... DHR ) announced that Executive Vice President and ... at the Goldman Sachs Global,Industrials Conference in New ... a.m. EST. The audio will be simultaneously webcast ... a leading manufacturer of Professional,Instrumentation, Medical Technologies, Industrial ...
... CLARA, Calif., Oct. 28 Align,Technology, Inc. (Nasdaq: ALGN ... 2008, ended September 30, 2008., Total net revenues for ... compared to $71.5 million reported in the third quarter of,2007 ... second quarter,of 2008 (Q2 08)., On a generally accepted ...
Cached Medicine News:Health News:Cialis May Help Ease Pulmonary Hypertension 2Health News:WellPoint Announces Appearances at Upcoming Conferences 2Health News:Agency Takes Adverse Decision to Biopure's Product Registration in South Africa 2Health News:Agency Takes Adverse Decision to Biopure's Product Registration in South Africa 3Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 2Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 3Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 4Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 5Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 6Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 7Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 8Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 9Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 10Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 11Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 12Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 13Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 14
The ultimate combination of comfort, convenience and affordability, recommended for daily wear, also approved for extended wear (1-7 days)....
SofLens Multi-Focal with unique Natra-Sight Optics designed to provide broad transition for near, intermediate and far vision, SofLens Multi-Focal lenses offer crisp, clear vision at all distances....
... With the Hertel, the unit ... and held firmly against the ... with the center of the ... the two temporal orbital walls, ...
Fastest, easiest and least expensive method for measuring exophthalmos. By sighting at right angles, this device eliminates parallax and allows the clinician to measure the amount of protrusion or bu...
Medicine Products: